Stefania Mondello
Anwarul Hasan
Deborah A. Shear- 1Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
- 2Department of Mechanical and Industrial Engineering, College of Engineering, Qatar University, Doha, Qatar
- 3Brain Trauma Neuroprotection Branch, Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MD, United States
Editorial on the Research Topic
Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges
Traumatic brain injury (TBI) constitutes a critical health problem. More than 50 million new cases occur worldwide each year, accounting for upwards of a million deaths (roughly 2,700 deaths per day) and a global financial burden of $US400 billion (1, 2). Overall, TBI-related disability is increasing globally, negatively affecting families and society, as well as health-care systems and economies (2). Among survivors, nearly half of those with moderate or severe TBI require years of intensive therapy and face substantial functional impairment and reduced life expectancy (3); however, also mild TBIs and concussions can lead to persistent adverse outcomes.
Despite thousands of preclinical studies in laboratory animals and hundreds of randomized controlled clinical trials (RCTs) testing neuroprotection approaches with different pathophysiological targets (4, 5), to date, no intervention has demonstrated to be unequivocal effective and improve the long-term functional outcome following TBI (1, 6).
This book incorporates reviews and research articles from leaders in the field describing promising therapeutic avenues, which span the spectra of TBI severity and have undergone experimental and clinical investigation. What emerges is a panoramic view of a field actively exploring alternative strategies and novel directions, such as preclinical-drug screening multimodel multispecies consortia (Kochanek et al.) (7, 8), capable to tackle the challenge of heterogeneity in TBI.
Recognizing the critical neuronal loss and wide variability existing in pathophysiologic mechanisms triggered by TBI, the current focus is on the regenerative potential and pleiotropic neuroprotective properties of stem cell therapy for TBI (9, 10). Accordingly, diverse authors have provided perspectives with respect to the application of mesenchymal stromal cells (MSCs) (Carbonara et al.) and the anti-inflammatory role of neural stem cell transplantation (Kassi et al.), and also generated new compelling data (Nasser et al.).
Sophisticated experiments reinterpreting previous unsuccessful therapeutic interventions (11, 12), including erythropoietin (Robinson et al.), hypothermia (Szczygielski et al.), and selective brain cooling (Leung et al.) have also been conducted providing authors with the opportunity to identify potential reasons for clinical failure. In this analysis, a complex array of factors, comprising a lack of precise diagnose and endophenotype characterization, inadequate measures of outcomes, and tools to inform tailored and individualized treatment emerges as main barriers to advance clinical care in TBI (13). Complementing this conceptual framework, a strong emphasis has also been placed by several contributors on the need for a mechanistic approach to guide drug development. This strategy can better inform target selection and streamline the hard translational decision process. As a consequence, investigations on mitochondrial dysfunction (Pandya et al.), microglial activation (Madathil et al.), cerebral microcirculation impairment (Bellapart et al.), and gut dysbiosis (Rice et al.) following TBI are presented, highlighting their directly involvement in disease pathogenesis and outcome, and role as therapeutic target candidates.
Finally, the volume includes experimental and human studies which add further evidence for the use of neuroimaging (Bajaj et al.) and biofluid markers (Bhatti et al. and DeDominicis et al.) as surrogate endpoints of clinical benefit and treatment response after therapeutic intervention in TBI, supporting their incorporation in future clinical trials (14). Imaging and biofluid markers can, in fact, be instrumental in identifying and characterizing pathophysiologic mechanisms leading to more accurate and finer-grained disease classification which, in turn, may be used to enrich or stratify patient groups, to demonstrate target engagement, and/or as proof of treatment efficacy (14–16). These factors can play a transformative role in designing effective clinical trials, increasing treatment effectiveness as well as reducing healthcare costs (16–18).
Overall, this volume is intended to provide novel perspectives and insights into the critical research area of TBI treatment, foster knowledge and innovation in the arena of drug development, and stimulates new frameworks and testable hypotheses that can help inform and refine the next generation of TBI clinical trials.
We thank our colleagues for devoting their time, efforts, and clinical and scientific experience. This book would not have been possible without their important contributions. We also thank the editorial team for their dedicated support and assistance. Last, and most important, we are indebted to all patients with TBI and their families for their invaluable contributions. They represent our greatest source of inspiration and all our endeavors are directed toward improving their outcome and quality of life.
Author Contributions
SM wrote the original draft, assembled and incorporated comments from the co-authors, and crafted the final draft. All of the other co-authors contributed to manuscript review and revision.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. (2017) 16:987–1048. doi: 10.1016/S1474-4422(17)30371-X
2. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. (2019) 18:56–87. doi: 10.1016/S1474-4422(18)30415-0
3. Stocchetti N, Carbonara M, Citerio G, Ercole A, Skrifvars MB, Smielewski P, et al. Severe traumatic brain injury: targeted management in the intensive care unit. Lancet Neurol. (2017) 16:452–64. doi: 10.1016/S1474-4422(17)30118-7
4. DeWitt DS, Hawkins BE, Dixon CE, Kochanek PM, Armstead W, Bass CR, et al. Pre-Clinical testing of therapies for traumatic brain injury. J Neurotrauma. (2018) 35:2737–54. doi: 10.1089/neu.2018.5778
5. Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, et al. A state-of-the-science overview of randomized controlled trials evaluating acute management of moderate-to-severe traumatic brain injury. J Neurotrauma. (2016) 33:1461–78. doi: 10.1089/neu.2015.4233
6. Maas AI, Murray GD, Roozenbeek B, Lingsma HF, Butcher I, McHugh GS, et al. Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research. Lancet Neurol. (2013) 12:1200–10. doi: 10.1016/S1474-4422(13)70234-5
7. Kochanek PM, Bramlett HM, Dixon CE, Dietrich WD, Mondello S, Wang KKW, et al. Operation brain trauma therapy: 2016 update. Military Med. (2018) 183:303–12. doi: 10.1093/milmed/usx184
8. Kochanek PM, Bramlett HM, Dixon CE, Shear DA, Dietrich WD, Schmid KE, et al. Approach to modeling, therapy evaluation, drug selection, and biomarker assessments for a multicenter pre-clinical drug screening consortium for acute therapies in severe traumatic brain injury: operation brain trauma therapy. J Neurotrauma. (2016) 33:513–22. doi: 10.1089/neu.2015.4113
9. Hasan A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, et al. Mesenchymal stem cells in the treatment of traumatic brain injury. Front Neurol. (2017) 8:28. doi: 10.3389/fneur.2017.00028
10. Zibara K, Ballout N, Mondello S, Karnib N, Ramadan N, Omais S, et al. Combination of drug and stem cells neurotherapy: potential interventions in neurotrauma and traumatic brain injury. Neuropharmacology. (2019) 145:177–98. doi: 10.1016/j.neuropharm.2018.09.032
11. Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC, et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. (2014) 312:36–47. doi: 10.1001/jama.2014.6490
12. Clifton GL, Valadka A, Zygun D, Coffey CS, Drever P, Fourwinds S, et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol. (2011) 10:131–9. doi: 10.1016/S1474-4422(10)70300-8
13. Stein DG. Embracing failure: what the Phase III progesterone studies can teach about TBI clinical trials. Brain Inj. (2015) 29:1259–72. doi: 10.3109/02699052.2015.1065344
14. Mondello S, Shear DA, Bramlett HM, Dixon CE, Schmid KE, Dietrich WD, et al. Insight into pre-clinical models of traumatic brain injury using circulating brain damage biomarkers: operation brain trauma therapy. J Neurotrauma. (2016) 33:595–605. doi: 10.1089/neu.2015.4132
15. Manley GT, MacDonald CL, Markowitz A, Stephenson D, Robbins A, Gardner RC, et al. The traumatic brain injury endpoints development (TED) initiative: progress on a public-private regulatory collaboration to accelerate diagnosis and treatment of traumatic brain injury. J Neurotrauma. (2017) 34:2721–30. doi: 10.1089/neu.2016.4729
16. Jeromin A, Maas AI, Buki A, Mondello S. Developing a molecular taxonomy for traumatic brain injury: a perspective to enable the development of diagnostics and therapeutics. Biomark Med. (2015) 9:619–21. doi: 10.2217/bmm.15.22
17. Roozenbeek B1, Lingsma HF, Maas AI. New considerations in the design of clinical trials for traumatic brain injury. Clin Investig. (2012) 2:153–62. doi: 10.4155/cli.11.179
Keywords: traumatic brain injury (TBI), neuroprotection, therapy, translational research, drug development, clinical trial design, mesenchymal stem cells, phenotyping
Citation: Mondello S, Hasan A and Shear DA (2019) Editorial: Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges. Front. Neurol. 10:1326. doi: 10.3389/fneur.2019.01326
Received: 21 November 2019; Accepted: 02 December 2019;
Published: 17 December 2019.
Edited and reviewed by: Mårten Risling, Karolinska Institutet (KI), Sweden
Copyright © 2019 Mondello, Hasan and Shear. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stefania Mondello, c3RtX21vbmRlbGxvJiN4MDAwNDA7aG90bWFpbC5jb20=